Materias dentro de su búsqueda.
Mostrando 927,121 - 927,140 Resultados de 928,171 Para Buscar '"8½"', tiempo de consulta: 5.09s Limitar resultados
  1. 927121
    “…Trial 1 and 2 findings were discordant for the mean length of stay outcome (Trial 1: 5.5 versus 6.3 days; estimated effect size difference 1.3 days [0.9 to 1.8], p < 0.001, CI was both above and below non-inferiority margin; Trial 2: 5.9 versus 5.0 days; estimated effect size difference −1.6 days [−2.0 to −1.1], p < 0.001, CI was completely below non-inferiority margin). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Impact of disinvestment from weekend allied health services across acute medical and surgical wards: 2 stepped-wedge cluster randomised controlled trials
  2. 927122
    “…Assuming an average meal of 600 kcal, energy labelling on menus would reduce energy purchased per meal by 7.8% (95% CI 2.5% to 13.1%). The quality of the evidence for these three studies was rated as low, so our confidence in the effect estimate is limited and may change with further studies. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Nutritional labelling for healthier food or non‐alcoholic drink purchasing and consumption
  3. 927123
    “…SEARCH METHODS: We searched the Cochrane Bone, Joint and Muscle Trauma Group Specialised Register (August 2017); Cochrane Central Register of Controlled Trials (2017, Issue 8); and MEDLINE, Embase, CINAHL and trial registers to August 2017. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Interventions for preventing falls in older people in care facilities and hospitals
  4. 927124
    “…SSYX also increased the mRNA and protein expression of PGC-1α (0.25 μg/ml, 0.8892 ± 0.0848 vs. 1.0970 ± 0.0994, t = 4.319, P = 0.0013; 0.5 μg/ml, 0.8892 ± 0.0848 vs. 1.2330 ± 0.0564, t = 7.150, P < 0.0001; and 1.0 μg/ml, 0.8892 ± 0.0848 vs. 1.1640 ± 0.0755, t = 5.720, P < 0.0001; n = 5 per dosage group), AMPK (0.25 μg/ml, 0.8872 ± 0.0779 vs. 1.1500 ± 0.0507, t = 7.239, P < 0.0001; 0.5 μg/ml, 0.8872 ± 0.0779 vs. 1.2280 ± 0.0623, t = 9.379, P < 0.0001; and 1.0 μg/ml, 0.8872 ± 0.0779 vs. 1.3020 ± 0.0450, t = 11.400, P < 0.0001; n = 5 per dosage group), CPT-1 (1.0 μg/ml, 0.7348 ± 0.0594 vs. 0.9880 ± 0.0851, t = 4.994, P = 0.0007, n = 5), and GLUT-4 (0.5 μg/ml, 1.5640 ± 0.0599 vs. 1.7720 ± 0.0660, t = 3.783, P = 0.0117; 1.0 μg/ml, 1.5640 ± 0.0599 vs. 2.0490 ± 0.1280, t = 8.808, P < 0.0001; n = 5 per dosage group). The effect became more obvious with the increasing concentration of SSYX. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Effect of the Shensong Yangxin Capsule on Energy Metabolism in Angiotensin II-Induced Cardiac Hypertrophy
  5. 927125
    “…At W96, B/F/TAF was noninferior to DTG/ABC/3TC: 87.9% vs. 89.8%, respectively, achieved HIV-1 RNA <50 copies/mL (difference −1.9%; 95%CI −6.9% to 3.1%, P = 0.45). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    LB4. A Phase 3, Randomized, Controlled Clinical Trial of Bictegravir in a Fixed-Dose Combination, B/F/TAF, vs. ABC/DTG/3TC in Treatment-Naïve Adults at Week 96
  6. 927126
    “…Top MTRs were DTG + TDF/FTC (69/517, 13%), DRV + RTV + TDF/FTC (60/517, 12%), and DRV/c + TDF/FTC (40/517, 8%). Average persistency for STRs was significantly longer at 252 days vs. 233 days for MTRs (P = 0.002). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    550. Adherence and Persistency With Modern Single vs. Multi-Tablet Antiretroviral (ARV) Regimens in First Treatment of HIV in Clinical Practice
  7. 927127
    “…Amsterdam: Academic Press; 2017. 808 p. 8. Shen B, Tang H, Jiang X, editors. Translational Biomedical Informatics: A Precision Medicine Perspective. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    3339 Development of a Competency-based Informatics Course for Translational Researchers
  8. 927128
    por Tafuto, Barbara Ann
    Publicado 2019
    “…A CTSA Website is used as a tool when it provides the functionality within its web design like providing an online application or database, or interactive training pages. In 8 of the 9 articles, authors reported on CTSA institutional website as either a translational informatics portal or providing informatics functionalities. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    3355 The CTSA Institutional website: A higher purpose - Researcher use of institutional Clinical and Translational Science Award (CTSA) website content to assess or promote NCATS CTSA Program Goals.
  9. 927129
    “…It was already demonstrated by Esteban et al., in a prospective study that patients with severe sepsis had a mortality rate of 26% when not admitted to an ICU in comparison to 11% when they were admitted to an ICU.(8) Meanwhile, we know that early referral is particularly important, because for ischemic diseases the timing appears to make a difference in terms of full recovery. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Surgical intensive care – current and future challenges?
  10. 927130
    “…Une équipe multidisciplinaire (comprenant des obstétriciens, des infirmières, des pédiatres, des spécialistes de la prévention des infections, des inhalothérapeutes et des anesthésiologistes) devrait être nommée au sein de chaque unité et être responsable de l’organisation et de la mise en œuvre des protocoles de prise en charge du SRAS de l’unité. (III-C); 8. Le personnel offrant des soins aux patientes enceintes atteintes du SRAS ne devraient pas offrir leurs services aux autres patientes enceintes. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Lignes directrices quant à la prise en charge des patientes en obstétrique chez lesquelles la présence du syndrome respiratoire aigu sévère (SRAS) est soupçonnée ou probable, et des nouveau-nés issus de ces patientes
  11. 927131
    “…Other travel related infections, especially viral haemorrhagic fevers, should also be considered. 8. The optimum diagnostic procedure is examination of thick and thin blood films by an expert to detect and speciate the malarial parasites. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    UK malaria treatment guidelines 2016
  12. 927132
    “…Une équipe multidisciplinaire (comprenant des obstétriciens, des infirmières, des pédiatres, des spécialistes de la prévention des infections, des inhalothérapeutes et des anesthésiologistes) devrait être nommée au sein de chaque unité et être responsable de l’organisation et de la mise en œuvre des protocoles de prise en charge du SRAS de l’unité (III-C). 8. Le personnel offrant des soins aux patientes enceintes atteintes du SRAS ne devraient pas offrir leurs services aux autres patientes enceintes. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    N(o) 225-Lignes directrices quant à la prise en charge des patientes en obstétrique chez lesquelles la présence du syndrome respiratoire aigu sévère (SRAS) est soupçonnée ou probable, et des nouveau-nés issus de ces patientes
  13. 927133
    “…History of retinopathy of any etiology. 7. Psoriasis. 8. Porphyria. 9. Known bone marrow disorders with significant neutropenia (polymorphonuclear leukocytes <1500) or thrombocytopenia (<100 K). 10. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial
  14. 927134
    “…TRIAL STATUS: Protocol version 1.8, from April 16, 2020. Recruitment is ongoing (first patient recruited April 6, 2020; final patient expected to be recruited October 31, 2020). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial
  15. 927135
    “…The first-trimester (gestational age, 6–8 weeks) human placenta-decidua tissue was obtained from 11 to 15 healthy women undergoing elective termination of pregnancy. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Periconceptional exposure to lopinavir, but not darunavir, impairs decidualization: a potential mechanism leading to poor birth outcomes in HIV-positive pregnancies
  16. 927136
    “…Documented interstitial pneumonia requiring admission and at least two of the following parameters: 1) Fever ≥ 37.8°C (tympanic) 2) IL-6 in serum ≥ 25 pg/mL (in the absence of a previous dose of prednisone or equivalent> 1 mg / kg) or PCR> 5mg/dL 3) Lymphocytes <600 cells/mm(3) 4) Ferritin> 300 μg/L that doubles in 24 hours 5) Ferritin> 600 μg/L in the first determination and LDH> 250 U/L 6) D-dimer (> 1 mg/L) d. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial
  17. 927137
    “…However, when formally considering ECMO, a trial of Anakinra 4 mg/kg increasing to 8 mg/kg twice daily over 4 days (day 5–9) was commenced. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    O16 Learning from acute COVID-19in a patient with potential immune dysregulation
  18. 927138
    “…In stage 1, healthy adults (aged ≥18 years) residing in or near Kambia district, received an intramuscular injection of Ad26.ZEBOV (5×10(10) viral particles) on day 1 (first dose) followed by an intramuscular injection of MVA-BN-Filo (1×10(8) infectious units) on day 57 (second dose). An Ad26.ZEBOV booster vaccination was offered at 2 years after the first dose to stage 1 participants. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial
  19. 927139
    por de las Fuentes, Lisa, Sung, Yun Ju, Noordam, Raymond, Winkler, Thomas, Feitosa, Mary F., Schwander, Karen, Bentley, Amy R., Brown, Michael R., Guo, Xiuqing, Manning, Alisa, Chasman, Daniel I., Aschard, Hugues, Bartz, Traci M., Bielak, Lawrence F., Campbell, Archie, Cheng, Ching-Yu, Dorajoo, Rajkumar, Hartwig, Fernando P., Horimoto, A.R.V.R., Li, Changwei, Li-Gao, Ruifang, Liu, Yongmei, Marten, Jonathan, Musani, Solomon K., Ntalla, Ioanna, Rankinen, Tuomo, Richard, Melissa, Sim, Xueling, Smith, Albert V., Tajuddin, Salman M., Tayo, Bamidele O., Vojinovic, Dina, Warren, Helen R., Xuan, Deng, Alver, Maris, Boissel, Mathilde, Chai, Jin-Fang, Chen, Xu, Christensen, Kaare, Divers, Jasmin, Evangelou, Evangelos, Gao, Chuan, Girotto, Giorgia, Harris, Sarah E., He, Meian, Hsu, Fang-Chi, Kühnel, Brigitte, Laguzzi, Federica, Li, Xiaoyin, Lyytikäinen, Leo-Pekka, Nolte, Ilja M., Poveda, Alaitz, Rauramaa, Rainer, Riaz, Muhammad, Rueedi, Rico, Shu, Xiao-ou, Snieder, Harold, Sofer, Tamar, Takeuchi, Fumihiko, Verweij, Niek, Ware, Erin B., Weiss, Stefan, Yanek, Lisa R., Amin, Najaf, Arking, Dan E., Arnett, Donna K., Bergmann, Sven, Boerwinkle, Eric, Brody, Jennifer A., Broeckel, Ulrich, Brumat, Marco, Burke, Gregory, Cabrera, Claudia P., Canouil, Mickaël, Chee, Miao Li, Chen, Yii-Der Ida, Cocca, Massimiliano, Connell, John, de Silva, H. Janaka, de Vries, Paul S., Eiriksdottir, Gudny, Faul, Jessica D., Fisher, Virginia, Forrester, Terrence, Fox, Ervin F., Friedlander, Yechiel, Gao, He, Gigante, Bruna, Giulianini, Franco, Gu, Chi Charles, Gu, Dongfeng, Harris, Tamara B., He, Jiang, Heikkinen, Sami, Heng, Chew-Kiat, Hunt, Steven, Ikram, M. Arfan, Irvin, Marguerite R., Kähönen, Mika, Kavousi, Maryam, Khor, Chiea Chuen, Kilpeläinen, Tuomas O., Koh, Woon-Puay, Komulainen, Pirjo, Kraja, Aldi T., Krieger, J.E., Langefeld, Carl D., Li, Yize, Liang, Jingjing, Liewald, David C.M., Liu, Ching-Ti, Liu, Jianjun, Lohman, Kurt K., Mägi, Reedik, McKenzie, Colin A., Meitinger, Thomas, Metspalu, Andres, Milaneschi, Yuri, Milani, Lili, Mook-Kanamori, Dennis O., Nalls, Mike A., Nelson, Christopher P., Norris, Jill M., O’Connell, Jeff, Ogunniyi, Adesola, Padmanabhan, Sandosh, Palmer, Nicholette D., Pedersen, Nancy L., Perls, Thomas, Peters, Annette, Petersmann, Astrid, Peyser, Patricia A., Polasek, Ozren, Porteous, David J., Raffel, Leslie J., Rice, Treva K., Rotter, Jerome I., Rudan, Igor, Rueda-Ochoa, Oscar-Leonel, Sabanayagam, Charumathi, Salako, Babatunde L., Schreiner, Pamela J., Shikany, James M., Sidney, Stephen S., Sims, Mario, Sitlani, Colleen M., Smith, Jennifer A., Starr, John M., Strauch, Konstantin, Swertz, Morris A., Teumer, Alexander, Tham, Yih Chung, Uitterlinden, André G., Vaidya, Dhananjay, van der Ende, M. Yldau, Waldenberger, Melanie, Wang, Lihua, Wang, Ya-Xing, Wei, Wen-Bin, Weir, David R., Wen, Wanqing, Yao, Jie, Yu, Bing, Yu, Caizheng, Yuan, Jian-Min, Zhao, Wei, Zonderman, Alan B., Becker, Diane M., Bowden, Donald W., Deary, Ian J., Dörr, Marcus, Esko, Tõnu, Freedman, Barry I, Froguel, Philippe, Gasparini, Paolo, Gieger, Christian, Jonas, Jost Bruno, Kammerer, Candace M., Kato, Norihiro, Lakka, Timo A., Leander, Karin, Lehtimäki, Terho, Magnusson, Patrik K.E., Marques-Vidal, Pedro, Penninx, Brenda W.J.H., Samani, Nilesh J., van der Harst, Pim, Wagenknecht, Lynne E., Wu, Tangchun, Zheng, Wei, Zhu, Xiaofeng, Bouchard, Claude, Cooper, Richard S., Correa, Adolfo, Evans, Michele K., Gudnason, Vilmundur, Hayward, Caroline, Horta, Bernardo L., Kelly, Tanika N., Kritchevsky, Stephen B., Levy, Daniel, Palmas, Walter R., Pereira, A.C., Province, Michael M., Psaty, Bruce M., Ridker, Paul M., Rotimi, Charles N., Tai, E. Shyong, van Dam, Rob M., van Duijn, Cornelia M., Wong, Tien Yin, Rice, Kenneth, Gauderman, W. James, Morrison, Alanna C., North, Kari E., Kardia, Sharon L.R., Caulfield, Mark J., Elliott, Paul, Munroe, Patricia B., Franks, Paul W., Rao, Dabeeru C., Fornage, Myriam
    Publicado 2020
    “…Through combined meta-analyses of Stages 1 and 2, we identified 84 known and 18 novel BP loci at genome-wide significance level (P<5×10(−8)). Two novel loci were identified based on the 1DF test of interaction with educational attainment, while the remaining 16 loci were identified through the 2DF joint test of genetic and interaction effects. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Gene-educational attainment interactions in a multi-ancestry genome-wide meta-analysis identify novel blood pressure loci
  20. 927140
    “…Exclusion criteria: (1) pregnant or breastfeeding women; (2) known allergy to ivermectin or some of the components of ivermectin tablets or placebo; (3) current use of home oxygen; (4) require hospitalization due to COVID-19 at the time of diagnosis or history of hospitalization for COVID-19; (5) presence of mal-absorptive syndrome; (6) presence of any other concomitant acute infectious disease; (7) known history of severe liver disease, for example liver cirrhosis; (8) need or use of antiviral drugs at the time of admission for another viral pathology other than COVID-19; (9) need or use of hydroxychloroquine or chloroquine; (10) use of ivermectin up to 7 days prior to randomization; (11) patients on dialysis or who have required it in the last 2 months or who plan to do it in the next 2 months; and (12) current participation or in the last 30 days in a research study that has included the administration of a drug (Table 1). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial
Herramientas de búsqueda: RSS